MedTrace Logo

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

NCT05304130 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-01-26

No results posted yet for this study

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) profiles of otilimab in healthy Japanese participants.

Conditions

  • Arthritis, Rheumatoid

Interventions

BIOLOGICAL

Otilimab

Otilimab will be administered via pre-filled syringe.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2023-05-04
Completion
2023-05-04

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304130 on ClinicalTrials.gov